Establishment of anti-mesothelioma monoclonal antibodies

about

Establishment of anti-mesothelioma monoclonal antibodies

Item

http://www.wikidata.org/entity/Q36061312

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Establishment of anti-mesothelioma monoclonal antibodies

@ast

Establishment of anti-mesothelioma monoclonal antibodies

@en

type

Item

label

Establishment of anti-mesothelioma monoclonal antibodies

@ast

Establishment of anti-mesothelioma monoclonal antibodies

@en

prefLabel

Establishment of anti-mesothelioma monoclonal antibodies

@ast

Establishment of anti-mesothelioma monoclonal antibodies

@en

P1476

Establishment of anti-mesothelioma monoclonal antibodies

@en

P2093

Chikao Morimoto

http://www.w3.org/2001/XMLSchema#string

Kazunori Kajino

http://www.w3.org/2001/XMLSchema#string

Masaaki Abe

http://www.w3.org/2001/XMLSchema#string

Midori Wakiya

http://www.w3.org/2001/XMLSchema#string

Naomi Ohtsuji

http://www.w3.org/2001/XMLSchema#string

Natsuko Mizutani

http://www.w3.org/2001/XMLSchema#string

Okio Hino

http://www.w3.org/2001/XMLSchema#string

Ryo Hatano

http://www.w3.org/2001/XMLSchema#string

Shuji Matsuoka

http://www.w3.org/2001/XMLSchema#string

P2860

Reactivity of a monoclonal antibody with human ovarian carcinoma

Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma

Continuous cultures of fused cells secreting antibody of predefined specificity

Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions

Malignant mesothelioma: facts, myths, and hypotheses

The cytology of malignant mesothelioma.

Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.

Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board.

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

Advances in malignant mesothelioma.

P2888

s13104-016-2128-x

P304

324

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13104-016-2128-X

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047323745

http://www.w3.org/2001/XMLSchema#string

P698

27342200

http://www.w3.org/2001/XMLSchema#string

P932

4921032

http://www.w3.org/2001/XMLSchema#string